Investment Partners LTD. Has $4.91 Million Holdings in Eli Lilly and Company $LLY

Investment Partners LTD. cut its holdings in Eli Lilly and Company (NYSE:LLY) by 3.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,300 shares of the company’s stock after selling 248 shares during the period. Eli Lilly and Company accounts for approximately 1.9% of Investment Partners LTD.’s portfolio, making the stock its 16th biggest holding. Investment Partners LTD.’s holdings in Eli Lilly and Company were worth $4,911,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of LLY. Wealth Preservation Advisors LLC bought a new position in shares of Eli Lilly and Company during the 1st quarter worth about $27,000. Blume Capital Management Inc. lifted its position in shares of Eli Lilly and Company by 46.7% in the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after acquiring an additional 14 shares during the period. IMG Wealth Management Inc. acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter worth approximately $35,000. TD Capital Management LLC raised its stake in shares of Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after purchasing an additional 31 shares in the last quarter. Finally, Family CFO Inc bought a new position in Eli Lilly and Company in the second quarter worth $54,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on LLY shares. HSBC lifted their target price on shares of Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. Cantor Fitzgerald increased their target price on Eli Lilly and Company from $925.00 to $985.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. BMO Capital Markets raised their price objective on shares of Eli Lilly and Company from $930.00 to $1,100.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Finally, Guggenheim reissued a “buy” rating and issued a $948.00 price target on shares of Eli Lilly and Company in a report on Thursday, October 16th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $990.11.

Eli Lilly and Company Price Performance

LLY opened at $1,021.41 on Thursday. The company has a fifty day simple moving average of $815.33 and a 200 day simple moving average of $778.16. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The stock has a market cap of $965.62 billion, a P/E ratio of 66.10, a P/E/G ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,022.42.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter in the prior year, the company earned $1.18 earnings per share. The business’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s payout ratio is 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.